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Abstract
Background: Women living with HIV are vulnerable to a variety of psychosocial barriers that limit access and
adherence to treatment. There is little evidence supporting interventions for improving access and treatment
adherence among vulnerable groups of women in low- and middle-income countries. The Mobile Phone-Based
Approach for Health Improvement, Literacy and Adherence (MAHILA) trial is assessing the feasibility, acceptability and
preliminary efficacy of a novel, theory-guided mobile health intervention delivered by nurses for enhancing self-care
and treatment adherence among HIV-infected women in India.
Methods/Design: Women (n = 120) with HIV infection who screen positive for depressive symptoms and/or other
psychosocial vulnerabilities are randomly assigned in equal numbers to one of two treatment arms: treatment as
usual plus the mobile phone intervention (experimental group) or treatment as usual (control group). In addition to
treatment as usual, the experimental group receives nurse-delivered self-care counselling via mobile phone at fixed
intervals over 16 weeks. Outcome measures are collected at baseline and at 4, 12, 24 and 36 weeks post-baseline.
Outcomes include antiretroviral treatment adherence, HIV-1 RNA, depressive symptoms, illness perceptions, internalized
stigma and quality of life.
Discussion: The MAHILA trial will provide information about how a mobile health counselling intervention delivered
by non specialist nurses may improve access to care and support the adherence and clinical outcomes of women with
HIV infection living in low- and middle-income countries such as India.
Trial registration: NCT02319330 (First received: July 30, 2014; Last verified: January 2016)
Keywords: HIV, Women, Mental health, mHealth, Antiretroviral adherence, LMIC
Background
There have been dramatic improvements in access to
life-saving combination antiretroviral therapy (cART). In
2014, 14.9 million people living with the human immuno-
deficiency virus (HIV) were receiving cART globally, 13.5
million of whom live in low- and middle-income countries
(LMICs) [1]. While cART has markedly improved the
prognosis of people living with HIV, deficits in adher-
ence to the spectrum of HIV care pose significant bar-
riers to its long term success [2–4]. Effective cART
requires optimal adherence to maintain suppression of
viral replication with non-adherence resulting in treat-
ment failure, disease progression and/or the emergence
of drug resistance [4–6].
Although India has seen a 19 % decline in new HIV in-
fections, the country has the third highest number of esti-
mated people living with HIV in the world (~2.1 million)
[7, 8], of whom, 39 % are women [9]. This amounts to
approximately 0.82 million women, given the large
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population of the country. There is a growing body of
evidence indicating that women in India are vulner-
able to poor HIV prevention and treatment outcomes
[10–18]. Women in India face a variety of inter-
related situational and psychosocial barriers that may
limit their access to HIV care and adherence to cART
over time including low literacy, stigma, discrimin-
ation and low social support [19–21]. Depression, a
prominent predictor of poor adherence to cART [22–26],
is also prevalent among women living with HIV in
India in whom it is largely under diagnosed and under-
treated [27, 28].
Good adherence is critical in HIV prevention and
treatment success, yet little attention has been given to
the development of interventions focused on women liv-
ing with HIV and depression or other psychosocial risk
factors for nonadherence. Interventions that improve
adherence and reduce the barriers that women face in
adhering to cART are urgently needed. Our preliminary
work indicates that a theory-guided phone intervention
originated in the U.S. is well suited to the Indian context
given the widespread use of mobile phone technology
[29]. This multi-dimensional, patient-centered approach
builds patient-provider rapport, establishes sources of sup-
port, and enables and empowers problem solving to ad-
dress situational and psychosocial barriers to care [29].
Other HIV adherence interventions using mobile health
(mHealth) approaches in LMIC’s have mainly relied on
text-based reminders [30–33]. Women with low literacy
skills may find text message based interventions challen-
ging. Further, these messages serve mainly as memory
prompts to take the medications and do not address psy-
chosocial factors that influence adherence behaviour [32].
Following initial formative work to refine the mobile
phone-based adherence intervention for delivery in India,
we trained non specialist nurses to deliver the interven-
tion. We are now evaluating whether the low cost,
mHealth counselling intervention is an effective, feasible
and acceptable way to improve the treatment outcomes of
women in India who are affected by HIV with and inter-
related mental health and psychosocial risk factors. Here
we describe the protocol of the ongoing randomized, sin-
gle blind (rater), controlled trial. The SPIRIT guidelines
were adhered to for the reporting of this manuscript.
Methods
Study aim and design
The MAHILA project is being conducted through a
Collaborative Research Partnership between investiga-
tors at the National Institute of Mental Health and
Neuro Sciences (NIMHANS) and Yale University. The
study is designed to evaluate the feasibility, acceptability,
fidelity and preliminary efficacy of a standardized mobile
phone intervention in a randomized, controlled pilot
study in which 120 HIV-infected women are randomized
to treatment as usual (TAU) alone or TAU plus the
mHealth (delivered over 16 weeks). After baseline assess-
ment, women are randomly assigned to treatment condi-
tion in a 1:1 allocation and outcomes (adherence, HIV-1
RNA plasma [viral load], mental health) are evaluated at
4, 12, 24 and 36 weeks post-randomization (see Fig. 1).
The primary hypothesis is that TAU plus the mobile
phone intervention will be more effective than TAU in
improving adherence to cART and clinical outcomes at
24 weeks post-randomization. Other hypotheses are
that the mobile phone intervention will be feasible and
acceptable to women living with HIV, fidelity of the
intervention will be maintained, and the intervention
will improve HIV adherence by concurrently addressing
prominent barriers (e.g., depressive symptoms) and im-
proving knowledge, support and problem solving for
better engagement in care and adherence.
Study setting
The Mobile Phone-Based Approach for Health Improve-
ment, Literacy and Adherence (MAHILA) project is con-
ducted at the government-sponsored HIV treatment clinic
(ART Centre) of the Belgaum Medical College Hospital, in
the state of Belgaum, Karnataka and at NIMHANS,
Bengaluru, South India. Recruitment of participants and
data collection is conducted by trained project staff at the
ART Centre in Belgaum. The mobile phone intervention
is delivered by trained non specialist nurses at NIMHANS.
Delivery of the intervention from a central site allows for
prevention of within site dispersion of intervention con-
tent to the control group and it enables close monitoring
of the fidelity of intervention delivery by the project inves-
tigators with mental health expertise at NIMHANS. These
non specialist nurses are trained as part of this study on
the clinical and psychosocial aspects of HIV/AIDS, basics
of mental health screening, phone based counseling and
the self-care intervention in four separate workshops.
Belgaum is situated in North-West Karnataka and shares
its borders with two neighbouring states – Maharashtra
and Goa. It is the largest district in the state with a popula-
tion of 4.8 million [34]. The district has the highest overall
HIV prevalence (1.43 %) in the state of Karnataka with
prevalence greater in rural than urban areas [35].
High rates of migration and a tradition called the Devdasi
system is prevalent in several parts of the district [36].
Devadasi is a religious practice whereby parents “marry a
daughter to a deity or a temple”. While the Devadasi prac-
tice has a long tradition in parts of India, many devadasis
today become religiously sanctioned prostitutes [37–39].
Sample size and eligibility criteria
One hundred and twenty participants will be enrolled,
with 60 in each treatment arm. This sample size is
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consistent with developmental research with the primary
aim of assessing the feasibility, acceptability and prelim-
inary efficacy of a new behavioral intervention [40]. It is
also large enough to allow for a diverse set of participant
characteristics representative of the target population.
To be eligible, a woman must be 1) able to give in-
formed consent, 2) able and willing to be contacted by
mobile phone, 3) 18 years of age or older, 4) speak
Kannada, English or Hindi, 5) HIV+ and taking cART
for less than six months, and 6) screen positive for depres-
sive symptoms or psychosocial risk factors. Women are
screened for depression with the Centre for Epidemiologic
Studies Depression Scale (CES-D) [41] and for psycho-
social risk factors with the Psychosocial Vulnerability
Checklist (PSVC). The PSVC was developed by the re-
searchers based on a review of studies among women with
HIV, especially in LMICs [26, 28, 42, 43]. It consists of 14
items which assess level of financial strain, social support,
violence, substance abuse, mental health problems and
suicide ideation.
Women are excluded from participation if they have
any condition that, in the opinion of the site investigator,
would compromise their ability to participate. Women
who screen positive for active suicidal ideation are also
Fig. 1 MAHILA flowchart
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excluded. All women with > 16 CES-D or active suicidal
thoughts are referred for treatment per a standardized,
written protocol.
Recruitment, enrollment and randomization
Potential participants are invited to participate by a
study team member in the ART Centre in Belgaum, who
then explains the study, obtains informed consent and
screens them for eligibility. Eligible participants then
complete the baseline assessments.
Each participant is provided with a basic mobile
phone. This mobile phone is used for proactive delivery
of the intervention to participants in the TAU +mobile
phone arm. To enhance methodological rigor, mobile
phones are also distributed to the participants in the TAU
arm to avoid a placebo effect and for ethical reasons: for
instance, the phone may be used by participants in either
arm to call the study nurse ad hoc for health-related
advice or assistance. It is also used by study staff for
purposes of establishing contact or collecting data if ne-
cessary. The mobile phones are provided with Sub-
scriber Identity Module (SIM) cards under a Closed
User Group (CUG) connection, in which the partici-
pant can make calls to the CUG number of the study
nurse and can receive calls from the same number. The
subscription is paid for by the project on a monthly
basis. This approach ensures that the phone is not used
for personal calls and it overcomes the difficulty of pro-
viding regular “top ups” of phone currency.
Participants are randomized to a treatment condition
following the baseline assessment in a 1:1 allocation
ratio to one of the two treatment arms. Computer-gen-
erated, block randomization is used to ensure balanced
representation in the two treatment arms. Sequentially
numbered opaque sealed envelopes serve as the allocation
concealment method. The Belgaum study staff are blinded
from the randomization assignment. Once a new par-
ticipant is enrolled, the Belgaum staff notify the project
coordinator who is located in the project research office
at NIMHANS. The project coordinator initiates the
randomization procedures and hand delivers notifica-
tion of randomization assignment to the study nurses
who then make contact with the participant by mobile
phone and inform them of the treatment assignment.
Study interventions
Control group – TAU All participants receive TAU as
prescribed by the Indian National ART guidelines [44].
In addition, referral to psychiatric care is made by pro-
ject staff for depressive symptoms or suicidal thoughts at
baseline and follow-up assessments. Further, as noted
above, all participants may initiate ad hoc contact with a
study nurse to confer about health-related matters. The
time, date, and content of any calls initiated by the
patient are documented by the nurse on a project form
for analysis. Time matched attention in both arms is not
possible given the individualized approach with variable
frequency and length of the intervention calls for each
participant.
Experimental group – TAU plus nurse-delivered
mobile phone intervention The mobile phone inter-
vention is delivered proactively by nurses via mobile
phones at a convenient time identified by the participant
for up to 16 weeks. Calls are made by the nurse at base-
line and at least two times per week during weeks 1–4,
once a week during weeks 5 to 10, and then at weeks 14
and 16. More frequent calls can be made at the discre-
tion of the nurse or if initiated by the participant as in
the TAU arm. Up to 6 attempts are made by the nurse
for each scheduled contact. As noted above, participants
also have the option of initiating calls to confer with the
nurse on health-related matters between scheduled calls
(date, length and content of each call are recorded by
the nurse). A script is used to guide delivery of the critical
elements of the manualized mobile phone intervention,
but the duration and content is individualized to each
participant.
The multi-component mobile phone intervention was
developed through a series of studies guided by applica-
tion of the Leventhal self-regulatory model of illness be-
havior to HIV [29]. It has been tested in the U.S. and
adapted for delivery to women in India during Phase 1
of project MAHILA. At the core of the approach is a
trained nurse who contacts patients proactively by mobile
phone at regular intervals. A structured, patient-centered,
counseling approach is used to engage and develop the
individual’s capacity for productive self-care behavior.
Self-care behavior of the individual living with a chronic
illness is essential to the effectiveness of medical treat-
ments since most of the day-to-day management takes
place outside of health care settings. A host of research
conducted by Leventhal and others has shown that the
way in which individuals interpret or make sense of their
illness (illness representation) drives the selection of cop-
ing/self-care behaviors (e.g., adherence to medication)
[45–51]. Illness representations are highly individual, in-
fluenced by a host of internal and external information
that are often ambiguous, fluctuate daily, and are affected
by situational variation. They may or may not be com-
patible with medical norms and influence how new
health information is processed and acted upon; any
health information provided will interact and be accepted
or rejected based on the patient’s pre-existing illness rep-
resentations. Thus, a central element of this mobile phone
intervention is assessing how the patient comprehends
her illness in the context of her life circumstances and
past experiences. Areas of risk and strengths are identified,
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corresponding health information and support is provided
and skills developed that are individualized to the patient’s
schema and situational context. The premise is that in so
doing the content is viewed as more meaningful and is more
readily integrated into the individual’s cognitive schema and
acted upon in problem solving efforts to manage barriers
and emotional responses that surround both the primary dif-
ficult experience of living with an illness condition in the
context of the individual’s situational challenges. Further, the
phone contact provides a means of facilitating coordination
of services, continuity of care, and patient monitoring.
The overarching objective is to ensure that the patient
in the TAU +mobile phone arm is provided with accur-
ate information and support, individualized to patient’s
knowledge level and situational context. This is intended
to stimulate development of a perceptual schema and
skills to engage resources and problem solve to manage
common barriers and emotional responses that surround
both the primary difficult experience of living with HIV
and taking antiretroviral therapy in the context of situ-
ational demands and challenges (e.g., stigma/disclosure,
competing demands/priorities (e.g., family/child care), side
effects, depressive symptoms, social support). A combin-
ation of strategies are used. The five-step process begins
with an assessment of the patient’s representation of HIV
and medication, areas of risk are identified, and corre-
sponding, key health information and affective support are
provided in accordance with the participant’s priorities
and contextualized to the patient’s schema and situational
context to build knowledge and skills to problem solve to
sustain adherence/self-care behavior as indicated. Appro-
priate referrals are generated as indicated.
The key components of the intervention include: (1)
providing the patient with an individualized program
that is congruent with patients’ social and cultural con-
text; (2) integrating screening for depression and other
concurrent risk factors; (3) enabling proactive problem
solving to aid participants in overcoming factors that
may impede their engagement in treatment; (4) improv-
ing early recognition of barriers and referrals; and, (5)
providing a mediator (the study nurse) between the health
system and the participants. For example, the study nurse
will screen for the presence or worsening of depression
and facilitate the engagement of the participants in appro-
priate mental health care by: (a) providing information
contextualized to the cognitive representation and con-
cerns (e.g., stigma/disclosure) of the patient; (b) schedul-
ing of appointments; (c) follow-up. This provides an
opportunity for continuity and coaching through threats
to treatment adherence that may manifest over time. The
sessions are interactive and patient-centered. The nurse
listens actively and uses theory-directed open-ended
questions and probes. Communication is positive, non-
judgmental and encouraging (See summary Table 1).
Fidelity To ensure treatment fidelity, the nurses are pro-
vided with Android smart phones so that the intervention
sessions can be recorded using an application. With the
consent of participants, the Android application is enabled
to record any incoming or outgoing calls made on the
phone which are saved on a secure laptop that is password
protected. The recorded calls are checked randomly by
the study principal investigators and the study nurses are
provided with feedback and guidance on the content and
delivery of counseling sessions as needed.
Measures
All study assessments (baseline and 4, 12, 24 and
36 weeks post-randomization) are conducted by trained
study staff who are blind to treatment allocation. Assess-
ments are typically conducted in person in the Belgaum
ART Centre, but there is some allowance for mobile
phone-based follow-up assessments in cases where par-
ticipants are unable to return to the study site. The data
from the forms can be exported in different formats,
such as Microsoft Excel file format (.xls) for further
processing.
Adherence is measured with the AIDS Clinical Trails
Group (ACTG) Adherence Questionnaire [52]. The ques-
tionnaire queries the patient on the number of doses
missed of an ART medication during each of the 4 days
before a clinic visit (e.g., “How many doses did you miss
yesterday, the day before yesterday, 3 days ago, and 4 days
ago?”). It has been used widely in the U.S. and India and
has shown good validity and reliability [53].
Plasma HIV-1 RNA concentration is used as the clin-
ical criterion and primary outcome variable. Plasma HIV
RNA concentration is measured in copies per millilitre
(Roche Amplicor HIV-1 Monitor Test). The threshold
for detectability of HIV viral load 50 copies/mL.
Table 1 Summary of key elements of the mobile phone
intervention
Key elements
1. Proactive, nurse-delivered calls by mobile phone at time convenient
to the participant;
2. Call sessions are interactive and patient-centered. The nurse listens
actively and uses theory-directed open-ended questions and probes.
Communication is positive, non-judgmental and encouraging.
3. Content of calls is individualized to the participant’s cognitive
representations, concerns (e.g., stigma/disclosure) and sociocultural
context;
4. Screening for depression and other concurrent psychosocial risk
factors;
5. Early recognition of barriers and referrals - Coaching through threats
to care that may manifest over time;
6. Building of problem solving skills to aid participants in overcoming
factors that may impede their engagement in treatment;
7. The nurse plays a mediating role between the health system and
the participant. Enhanced continuity of care.
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Depression is measured with the Centre for Epidemio-
logic Studies Depression Scale (CES-D) [41, 54]. CES-D
(α = 0.88-0.91) is a 20 item screening tool for depressive
symptomatology. All items are rated using a 4 point or-
dinal scale with the responses based on occurrence of
symptoms in the past one week.
Illness representation is measured with the Brief Illness
Perception Questionnaire (IPQ-B), a 9-item questionnaire
designed to rapidly assess cognitive and emotional repre-
sentations of illness [55]. The IPQ-B uses a single-item
scale approach to assess perception on a 0–10 response
scale, with higher scores representing more threatening
illness perceptions. The scale has demonstrated good
test-retest reliability (Pearson correlations 0.24-0.73)
and moderate to good correlations when tested for con-
current validity (Pearson correlations 0.32–0.63).
Symptom Distress is measured with the HIV Symptom
Index, a 20-item valid and reliable (α = 0.92) measure of
overall HIV symptom frequency and level of bother-
someness [56].
Stigma is measured with a 10-item measure of internal-
ized stigma. The scale was adapted from the Stigma Scale
which was developed in South India and measures enacted,
felt normative and internalised stigma [57]. Internalised
stigma experienced by respondents is measured on a 4
point scale running from 0 (not at all) to 3 (a great deal).
Quality of life is measured with the World Health
Organization (WHO) Quality of Life (QOL) HIV short
version (WHOQOL-HIV BREF), a multidimensional 31
item instrument used to assess quality of life of persons
with HIV [58]. WHOQOL-HIV BREF has been used and
validated in the Indian HIV population [59–61].
Feasibility, acceptability, and fidelity of the intervention
and study protocol are measured with protocol specific
tools. The assessment includes: 1) The ratio of eligible
study participants to those enrolled; 2) Number of sched-
uled study visits completed at 4, 12, 24, and 36 weeks; 3)
Attrition between baseline and follow-up; 4) Reason for pre-
mature drop-out; 5) Number of phone calls that were made
on schedule; 6) Level of participation in intervention sessions
including the total number sessions, number of sessions
completed without break offs, number of break offs,
length (minutes) of sessions; 7) Congruence of topic/
content discussed on calls with protocol; 8) Patient and
study nurse satisfaction with intervention content,
mode of delivery, and protocol; and, 9) Adverse events.
A study-specific intervention assessment tool is used to
evaluate content fidelity and quality of the interaction and a
log is maintained that details technical challenges faced by
the team (e.g., problems related to mobile phone, SIM card).
Data storage and monitoring
A web-accessible and interactive database system is used
for the storage and exploration of the study data. The
data collection framework uses an open-source relational
database management system, MySql, at the back-end
and Python-Django at the front end with a MVC
(Model-View-Controller) architecture. The MVC archi-
tecture makes it easy to develop new functionalities and
extend the capabilities of the framework. In the front-end
we have created forms for collecting the baseline and fol-
low-up data. The use of a data-collection framework of-
fers many advantages over conventional paper-based
forms. For example, sharing data across partners is easier
and the forms have a feature of preliminary validation, i.e.,
a user must enter values which are in the valid range
otherwise the form refuses to accept the input.
All study participants are assigned unique study identi-
fiers that appear on all data collection instruments,
tapes, documents, and files. Data collection instruments
and the study database contain no client identifying in-
formation or record of HIV status and are stored in a
secure, double-locked cabinet. Personal information
needed for tracking and informed consent are stored
separately from other data in double-locked, fireproof,
water resistant safe in the ART Centre. No identifying
information will leave the clinic or be entered into the
project database.
Data are entered into study-specific laptops. Microsoft
Access is used for storage and management. The master
study dataset is stored on a dedicated Windows file ser-
ver that can only be accessed by authorized study staff.
All data are password protected.
A Data Safety and Monitoring Board (DSMB) has been
constituted to review the progress and safety of study
procedures and address unanticipated problems involv-
ing risks to subjects or other serious adverse events. The
DSMB meets every three months.
Statistical analysis
Data will be described using univariate analysis (distribu-
tions, frequencies, and means). The intervention assign-
ment will be examined in relation to HIV-1 plasma and
cART adherence. Analyses will be intention-to-treat. As
this is a small sample size we will only be able to evalu-
ate parsimonious models to explore effect of the inter-
vention, and not include all mediating and potentially
confounding variables. Generalized estimating equations
(GEEs) will be used to model adherence rates to account
for the multiple measurements of each subject and allow
all subjects, regardless of the number of visits, to be in-
cluded in the analysis. Analyses also will be conducted
within-person, comparing baseline to follow-up session
responses. As GEEs require strong assumptions regarding
missing data (missing completely at random), analyses will
be repeated using the subset of subjects with complete
data.
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Discussion
To our knowledge, the current study is the first clinical
trial to examine the effects of a nurse delivered mobile
phone based self-care intervention for women with HIV
infection who have depression or psychosocial risk fac-
tors in a LMIC [32]. Results from this study will inform
the development of interventions for achieving improved
clinical benefits and recommendations for mHealth ser-
vice delivery, from the clinic to national and international
policy levels. Findings will also contribute to understand-
ing how mobile technology interventions motivate better
health and self-care among women with HIV. Further-
more, in addition to outcome data, respondent and pro-
vider satisfaction that are collected as part of this study
protocol may provide guidance to HIV and mHealth ex-
perts who are seeking to evaluate mobile phone programs
for HIV prevention, care, and treatment.
The protocol focuses on mHealth impact on psycho-
logical behavioral and physical health; assesses imple-
mentation issues unique to mHealth interventions; and
also looks at the gender intentionality of the intervention,
all of which are priorities for evidence generation in the
area of mobile phones for health among women in
LMICs. The study will also help us in identifying any risks
that women might face related to the mobile intervention
such as disclosure issues, any increase in stigma or escal-
ation of partner violence.
There are a few study limitations worth noting. Self-
reported adherence to cART has notable limitations
[62–65]. We have, however, measured HIV-1 RNA in
plasma which is the gold standard for monitoring the
efficacy of HIV treatment and measuring the validity of
adherence reports. If a patient’s virus is known to be
sensitive to current therapy, a detectable viral load likely
represents poor adherence [66]. The health behavior con-
structs we are assessing have not often been evaluated in
mobile phone interventions, but prior research and focus
group data from other projects suggests that the proposed
constructs are affected by mHealth programs [29, 67, 68].
In addition, we will not be able to control external factors
that may confound study results, such as medication sup-
plies or health system challenges, weather, civil or political
influences, or other health programs occurring in study
communities during the intervention period, although we
will document these contextual factors to help with inter-
pretation of findings.
The study has several strengths. It is the first trial
using a mHealth non text based intervention among
women with HIV infection in a LMIC; biases and con-
tamination have been minimised by adequate allocation
concealment and by ensuring that the teams of assessors
and interventionists are in two different geographical lo-
cations. The intervention itself is theory driven and is
based on the self-regulatory model of ART adherence
[29]. Both groups of women have been given mobile
phones to ensure blinding and remove any effect of
owning a phone rather than receiving an intervention.
Adequate training and supervision is provided to the
nurses including a periodic review of call recordings by
the investigators to ensure fidelity. Standard operating
procedures have been developed for women who report
mental health problems, suicidality or domestic violence.
Any adverse effects or difficulties related to the inter-
vention will be recorded. Multiple outcomes including
adherence, mental health outcomes, quality of life and
biological parameters of disease progression (e.g., HIV-1
RNA) are measured. An important outcome that has not
been studied in previous trial will include respondent and
provider satisfaction with the intervention.
Conclusions
This nurse led mobile phone intervention for improved
self-care among women with HIV infection who have
depression and/or psychosocial vulnerabilities will provide
important evidence for the usefulness, feasibility and ac-
ceptability of this novel intervention. Results of this trial
will be important in informing future mHealth interven-
tions for this population and for women with other
chronic medical illness in LMICs.
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